EDIT Editas Medicine, Inc. - Common Stock
$3,19
Prix · Aoû 19, 2026
Données fondamentales au Aoû 5, 2026
Fourchette 52 semaines
$2–$5
53% of range
Note des analystes
BUY
18 analysts
Objectif de cours
$6
+88% upside
P/E (TTM)
-1.8
ROE
-688.8%
Marge nette
-395.0%
À propos de Editas Medicine, Inc. - Common Stock Présentation de l'entreprise depuis Wikipedia
Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
Lire la suite
Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
History
Editas Medicine was originally founded with the name "Gengine, Inc." in September 2013 by Feng Zhang of the Broad Institute, Jennifer Doudna of the University of California, Berkeley, and George Church, David Liu, and J. Keith Joung of Harvard University, with funding from Third Rock Ventures, Polaris Partners and Flagship Ventures. The name was changed to the current "Editas Medicine" two months later. Doudna quit in June 2014 over legal differences concerning intellectual property of Cas9.
In August 2015, the company raised $120 million in Series B funding from Bill Gates and 13 other investors. it went public on 2 February 2016, via a $94 million initial public offering.
Editas entered into a strategic collaboration with Juno Therapeutics in 2015 to create a chimeric antigen receptor and high-affinity T cell receptor therapeutics to the end of developing cancer therapeutics. Juno was later acquired by Celgene, which was in turn acquired by Bristol Myers Squibb.
The company announced in 2015 that it was planning a clinical trial using CRISPR gene editing techniques to treat Leber congenital amaurosis type 10 (LCA10), a rare genetic illness that causes blindness. On 30 November 2018, the FDA gave permission to start the trials, under the investigational name EDIT-101 (also known as AGN-151587). In September 2021, a statement from Editas claimed that preliminary results from clinical trials were promising and support clinical benefits of EDIT-101 treatment.
In March 2020, Editas, in partnership with Allergan, was the first to use CRISPR to try to edit DNA inside a person's body (in vivo). As part of the clinical trial, a patient who was nearly blind as a result of Leber's congenital amaurosis received an intravitreal injection containing a harmless virus carrying CRISPR gene-editing instructions. Five months later, Editas reworked its deal with Allergan's owner AbbVie and regained full rights to their range of eye disease treatment therapies, including EDIT-101 for the treatment of LCA10.
In 2019, the company was building new chemistry facilities in Boulder, Colorado.
Katrine Bosley was CEO until 2019, when she was replaced by board member Cynthia Collins. Collins was replaced in 2021 by James Mullen, who had been board chairman. Gilmore O'Neill, former CMO of Sarepta Therapeutics, became CEO on June 1, 2022, with Mullen staying on as executive chairman of the board.
On December 12, 2024, Editas ended the development of reni-cel and laid off 65% of its employees.
Research
Editas works with two different CRISPR nucleases, Cas9 and Cas12a.
EDIT-101 is a CRISPR based gene therapy for treatment of Leber congenital amaurosis, currently in clinical trials.
EDIT-301 is an experimental potential treatment utilizing the firm's CAS 12a editing technology for sickle cell disease and beta-thalassemia. In 2019 the firm reported early success in research on the drug;. In December 2020, it filed an IND application for treatment of sickle cell disease. In January 2021, it said it had received clearance from the FDA for phase 1 safety studies.
== References ==
Source : Wikipedia (Anglais), CC BY-SA 4.0 · Voir sur Wikipedia ↗
EDIT Aperçu de l'action Prix, capitalisation boursière, P/E, EPS, ROE, dette/capitaux propres, fourchette sur 52 semaines
Prix
$3.19
Capitalisation Boursière
$312M
P/E (TTM)
-1.8
BPA (TTM)
$-1.80
Revenus (TTM)
$41M
Rendement div.
—
ROE
-688.8%
Dette/Capitaux propres
2.1
Fourchette 52 semaines
$2 – $5
EDIT Graphique du cours de l'action OHLCV quotidien avec indicateurs techniques — panoramique, zoom et personnalisez votre vue
Configure
Performance sur 10 ans Tendances du chiffre d'affaires, du bénéfice net, des marges et du BPA
Revenus et bénéfice net
$41M
2016-12-31
→
2025-12-31
BPA
$-1.80
2019-12-31
→
2025-12-31
Flux de trésorerie libre
$-166M
2016-12-31
→
2025-12-31
Marges
-395.0%
Valorisation Ratios P/E, P/S, P/B, EV/EBITDA — l'action est-elle chère ou bon marché ?
Métrique
Tendance sur 5 ans
EDIT
Médiane des pairs
P/E (TTM)
-1.8
17.4
P/S (TTM)
7.7
52.3
P/B
11.4
4.8
EV / EBITDA
-1.4
—
Price / FCF (Cours / FCF)
-1.9
—
Rentabilité Marges brutes, d'exploitation et nettes ; ROE, ROA, ROIC
Métrique
Tendance sur 5 ans
EDIT
Médiane des pairs
Operating Margin (Marge d'exploitation)
-394.9%
—
Net Profit Margin (Marge nette)
-395.0%
-670.1%
ROA
-60.6%
-41.1%
ROE
-688.8%
-52.6%
Santé financière Dette, liquidité, solvabilité — solidité du bilan
Métrique
Tendance sur 5 ans
EDIT
Médiane des pairs
Debt / Equity (Dette / Capitaux propres)
2.1
—
Current Ratio (Ratio de liquidité)
3.5
7.7
Quick Ratio (Ratio de liquidité réduite)
3.5
—
Croissance Croissance du chiffre d'affaires, du BPA et du bénéfice net : Année/Année, TCAC 3 ans, TCAC 5 ans
Métrique
Tendance sur 5 ans
EDIT
Médiane des pairs
Revenue YoY (Chiffre d'affaires YoY)
25.4%
—
Revenue CAGR 3Y (CAGR du chiffre d'affaires 3 ans)
27.2%
—
Revenue CAGR 5Y (CAGR du chiffre d'affaires 5 ans)
-14.9%
—
Efficacité du capital Rotation des actifs, rotation des stocks, rotation des créances
Métrique
Tendance sur 5 ans
EDIT
Médiane des pairs
EDIT Consensus des analystes Opinions des analystes haussières et baissières, objectif de cours à 12 mois, potentiel de hausse
ACHAT
18 analystes
- Achat fort 4 22,2%
- Achat 8 44,4%
- Conserver 4 22,2%
- Vente 2 11,1%
- Vente forte 0 0,0%
Objectif de cours à 12 mois
8 analystes · 2026-08-16
Médiane
$5.00
Maintenant
$3.19
Bas
$1.00
Haut
$15.00
Objectif médian
$5.00
+57,0%
Objectif moyen
$6.00
+88,4%
Historique des bénéfices BPA réel vs estimation, surprise %, taux de succès, prochaine date de publication des résultats
Surprise Moyenne
-0.03%
| Période | EPS Actual | BPA est. | Surprise |
|---|---|---|---|
| 30 juin 2026 | $-0.15 | $-0.28 | 0.13% |
| 31 mars 2026 | $-0.26 | $-0.27 | 0.01% |
| 31 décembre 2025 | $-0.06 | $-0.26 | 0.20% |
| 30 septembre 2025 | $-0.28 | $-0.30 | 0.02% |
| 30 juin 2025 | $-0.63 | $-0.38 | -0.25% |
| 31 mars 2025 | $-0.92 | $-0.60 | -0.32% |
Comparaison des pairs (sous-secteur GICS) Indicateurs clés par rapport aux pairs du secteur
| Ticker | Capitalisation Boursière | P/E | Revenus Année/Année | Marge Nette | ROE | Marge Brute |
|---|---|---|---|---|---|---|
| EDIT | $201M | -1.1 | 25.4% | -395.0% | -688.8% | — |
| CABA | $220M | -1.0 | — | — | -115.5% | — |
| VSTM | $600M | -2.6 | 209.1% | -677.6% | -449.2% | — |
| ZURA | — | — | — | — | — | — |
| MPLT | $773M | -0.9 | — | — | -151.1% | — |
| OCGN | $422M | -5.6 | 8.8% | -1537.4% | 1488.8% | — |
| PBYI | $300M | 9.8 | -0.91% | 13.6% | 26.5% | — |
| QTTB | $43M | 1.4 | — | 55.5% | 200.3% | — |
| RZLT | $388M | -4.6 | — | — | -56.9% | — |
| CMPX | $958M | — | — | — | -45.9% | — |
Fondamentaux complets Tous les indicateurs par an — compte de résultat, bilan, flux de trésorerie
Compte de résultat 13
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $41M | $32M | $78M | $20M | $26M | $91M | $21M | $32M | $14M | $6M | |
| R&D Expense | $90M | $199M | $178M | $175M | $143M | $158M | $97M | $91M | $83M | $57M | |
| SG&A Expense | $50M | $72M | $70M | $71M | $76M | $68M | $65M | $55M | $51M | $46M | |
| Operating Expenses | $201M | $283M | $247M | $246M | $219M | $226M | $161M | $146M | $134M | $103M | |
| Operating Income | $-160M | $-251M | $-169M | $-226M | $-193M | $-135M | $-141M | $-114M | $-120M | $-97M | |
| Other Non-op | $-2M | $-3.0K | $-2M | $0 | $37.0K | $16M | $-137.0K | $328.0K | $587.0K | $-57.0K | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | · | · | · | · | · | |
| Net Income | $-160M | $-237M | $-153M | $-220M | $-193M | $-116M | $-134M | $-110M | $-120M | $-97M | |
| EPS (Basic) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | · | · | · | |
| EPS (Diluted) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | · | · | · | |
| Shares (Basic) | 88,745,908 | 82,338,220 | 75,965,633 | 68,664,822 | 67,619,388 | 58,609,389 | 49,983,329 | · | · | · | |
| Shares (Diluted) | 88,745,908 | 82,338,220 | 75,965,633 | 68,664,822 | 67,619,388 | 58,609,389 | 49,983,329 | · | · | · | |
| EBITDA | $-160M | $-251M | $-169M | $-226M | $-193M | $-135M | $-141M | $-114M | $-120M | $-97M |
Bilan 24
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $147M | $132M | $124M | $142M | $204M | $140M | $238M | $135M | $147M | $185M | |
| Short-term Investments | $0 | $138M | $199M | $203M | $296M | $262M | $219M | $234M | $183M | · | |
| Receivables | $15M | $16M | $10M | $5M | $267.0K | $6M | $418.0K | $30.0K | $679.0K | $88.0K | |
| Prepaid Expense | $2M | $3M | $8M | $7M | $7M | $11M | $6M | $6M | $2M | $2M | |
| Current Assets | $164M | $289M | $341M | $357M | $507M | $419M | $464M | $375M | $332M | $187M | |
| PP&E (Net) | $4M | $14M | $12M | $16M | $17M | $14M | $11M | $40M | $39M | $40M | |
| PP&E (Gross) | $32M | $46M | $38M | $37M | $33M | $25M | $18M | $47M | $44M | $42M | |
| Accum. Depreciation | $28M | $32M | $26M | $22M | $16M | $11M | $7M | $7M | $4M | $2M | |
| Other Non-current Assets | $3M | $5M | $9M | $5M | $7M | $5M | $5M | $5M | $2M | $2M | |
| Total Assets | $187M | $342M | $499M | $514M | $677M | $573M | $509M | $420M | $373M | $229M | |
| Accounts Payable | $3M | $5M | $8M | $10M | $5M | $6M | $6M | $5M | $4M | $5M | |
| Accrued Liabilities | $33M | $46M | $35M | $31M | $20M | $24M | $22M | $13M | $11M | $17M | |
| Current Liabilities | $46M | $77M | $63M | $60M | $47M | $58M | $60M | $36M | $37M | $33M | |
| Capital Leases | $12M | $20M | $24M | $33M | $16M | $19M | $23M | $32M | $33M | $35M | |
| Other Non-current Liabilities | $3M | $3M | $2M | $0 | · | $28M | $1.0K | $293.0K | $317.0K | $396.0K | |
| Total Liabilities | $159M | $207M | $150M | $154M | $124M | $179M | $246M | $184M | $165M | $95M | |
| Long-term Debt | $59M | $57M | $0 | · | · | · | · | · | · | · | |
| Total Debt | $59M | $57M | · | · | · | · | · | · | · | · | |
| Common Stock | $10.0K | $8.0K | $8.0K | $7.0K | $7.0K | $6.0K | $5.0K | $5.0K | $4.0K | $4.0K | |
| Retained Earnings | $-1.63B | $-1.47B | $-1.23B | $-1.08B | $-858M | $-665M | $-549M | $-416M | $-306M | $-186M | |
| AOCI | $0 | $268.0K | $198.0K | $-4M | $-493.0K | $-46.0K | $107.0K | $-29.0K | $-76.0K | · | |
| Stockholders' Equity | $27M | $134M | $349M | $361M | $554M | $394M | $262M | $236M | $208M | $135M | |
| Liabilities + Equity | $187M | $342M | $499M | $514M | $677M | $573M | $509M | $420M | $373M | $229M | |
| Shares Outstanding | 97,866,996 | 82,734,696 | 81,767,263 | 68,847,382 | 68,435,257 | 62,563,457 | 54,355,798 | 48,758,951 | 44,507,960 | 35,818,131 |
Flux de trésorerie 10
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $10M | $21M | $20M | $29M | $43M | $23M | $27M | $27M | $23M | $17M | |
| Restructuring | · | $12M | $0 | $0 | · | · | · | · | · | · | |
| Operating Cash Flow | $-165M | $-210M | $-132M | $-177M | $-164M | $-180M | $-41M | $-46M | $-9M | $-50M | |
| CapEx | $607.0K | $9M | $5M | $4M | $8M | $7M | $6M | $5M | $2M | $3M | |
| Investing Cash Flow | $139M | $162M | $-4M | $114M | $-54M | $-141M | $12M | $-53M | $-184M | $-3M | |
| Stock Issued | $43M | $0 | $117M | $0 | $249M | $204M | $116M | $77M | $154M | $97M | |
| Net Stock Activity | $43M | $0 | $117M | · | $249M | $204M | $116M | $77M | $154M | $97M | |
| Financing Cash Flow | $40M | $56M | $118M | $1M | $282M | $224M | $132M | $87M | $155M | $97M | |
| Net Change in Cash | $14M | $8M | $-18M | $-62M | $64M | $-96M | $103M | $-12M | $-39M | $43M | |
| Free Cash Flow | $-166M | $-219M | $-137M | $-181M | $-172M | $-187M | $-47M | $-50M | $-11M | $-53M |
Rentabilité 5
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | · | · | |
| Net Margin | -395.0% | -733.7% | -196.1% | -1118.3% | -753.6% | -127.8% | -651.4% | -344.3% | · | · | |
| EBITDA Margin | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | · | · | |
| ROA | -60.6% | -56.4% | -30.2% | -37.0% | -30.8% | -21.4% | -28.8% | -27.7% | -40.0% | -51.3% | |
| ROE | -688.8% | -153.0% | -43.2% | -56.9% | -33.8% | -27.8% | -56.6% | -47.7% | -70.2% | -377.5% |
Liquidité et Solvabilité 4
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | 3.7 | 5.4 | 5.9 | 10.8 | 7.2 | 7.7 | 10.4 | 9.1 | 5.7 | |
| Quick Ratio | 3.5 | 3.7 | 5.3 | 5.8 | 10.7 | 7.0 | 7.6 | 10.3 | 9.0 | 5.6 | |
| Debt / Equity | 2.1 | 0.4 | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 2.0 | 0.4 | · | · | · | · | · | · | · | · |
Efficacité 2
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | 0.2 | 0.0 | 0.0 | 0.2 | 0.0 | 0.1 | · | · | |
| Receivables Turnover | 2.6 | 2.4 | 10.2 | 7.3 | 8.1 | 28.1 | 91.7 | 90.1 | · | · |
Taux de croissance 3
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 25.4% | -58.6% | 296.3% | -22.8% | -71.9% | · | · | · | · | · | |
| Revenue CAGR 3Y | 27.2% | 8.2% | -4.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -14.9% | · | · | · | · | · | · | · | · | · |
Valorisation (TTM) 14
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $41M | $32M | $78M | $20M | $26M | $91M | $21M | $32M | $14M | $6M | |
| Net Income TTM | $-160M | $-237M | $-153M | $-220M | $-193M | $-116M | $-134M | $-110M | $-120M | $-97M | |
| Market Cap | $201M | $105M | $828M | $611M | $1.82B | $4.39B | $1.61B | $1.11B | $1.37B | $581M | |
| Enterprise Value | $113M | $-107M | · | · | · | · | · | · | · | · | |
| P/E | -1.1 | -0.4 | -5.0 | -2.8 | -9.3 | -35.4 | -11.0 | · | · | · | |
| P/S | 5.0 | 3.3 | 10.6 | 31.0 | 71.1 | 48.3 | 78.4 | 34.7 | 99.6 | 96.0 | |
| P/B | 7.4 | 0.8 | 2.4 | 1.7 | 3.3 | 11.1 | 6.1 | 4.7 | 6.6 | 4.3 | |
| P / Tangible Book | 7.4 | 0.8 | 2.4 | 1.7 | 3.3 | 11.1 | · | · | · | · | |
| P / Cash Flow | -1.2 | -0.5 | -6.3 | -3.4 | -11.1 | -24.4 | -39.6 | -24.3 | -145.2 | -11.6 | |
| P / FCF | -1.2 | -0.5 | -6.1 | -3.4 | -10.6 | -23.5 | -34.4 | -22.0 | -119.2 | -10.9 | |
| EV / EBITDA | -0.7 | 0.4 | · | · | · | · | · | · | · | · | |
| EV / FCF | -0.7 | 0.5 | · | · | · | · | · | · | · | · | |
| EV / Revenue | 2.8 | -3.3 | · | · | · | · | · | · | · | · | |
| Earnings Yield | -87.8% | -226.8% | -19.9% | -36.2% | -10.7% | -2.8% | -9.0% | · | · | · |
Compte de résultat 12
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12M | $3M | $25M | $8M | $4M | $5M | $31M | $61.0K | $513.0K | $1M | $60M | $5M | $3M | $10M | $7M | $42.0K | |
| R&D Expense | $20M | $18M | $27M | $20M | $16M | $27M | $49M | $48M | $54M | $49M | $70M | $41M | $30M | $38M | $52M | $41M | |
| SG&A Expense | $12M | $10M | $11M | $12M | $13M | $13M | $16M | $18M | $18M | $19M | $14M | $15M | $17M | $23M | $18M | $16M | |
| Operating Expenses | $30M | $28M | $32M | $32M | $55M | $81M | $77M | $66M | $72M | $68M | $84M | $55M | $47M | $61M | $70M | $58M | |
| Operating Income | $-19M | $-25M | $-8M | $-25M | $-52M | $-76M | $-47M | $-66M | $-72M | $-67M | $-24M | $-50M | $-44M | $-51M | $-63M | $-58M | |
| Other Non-op | $17.0K | $-113.0K | $-5.0K | $-1.0K | $-2M | $-425.0K | $-3.0K | $-5.0K | $-1.0K | $6.0K | $-13.0K | $0 | $-7.0K | $-2M | $-2.0K | $1.0K | |
| Net Income | $-18M | $-25M | $-6M | $-25M | $-53M | $-76M | $-45M | $-62M | $-68M | $-62M | $-19M | $-45M | $-40M | $-49M | $-61M | $-56M | |
| EPS (Basic) | $-0.15 | $-0.26 | $0.03 | $-0.28 | $-0.63 | $-0.92 | $-0.55 | $-0.75 | $-0.82 | $-0.76 | $-0.20 | $-0.55 | $-0.56 | $-0.71 | $-0.88 | $-0.81 | |
| EPS (Diluted) | $-0.15 | $-0.26 | $0.03 | $-0.28 | $-0.63 | $-0.92 | $-0.55 | $-0.75 | $-0.82 | $-0.76 | $-0.20 | $-0.55 | $-0.56 | $-0.71 | $-0.88 | $-0.81 | |
| Shares (Basic) | 119,294,615 | 97,879,343 | -168,811,755 | 90,090,397 | 84,412,200 | 83,055,066 | -164,396,186 | 82,485,199 | 82,310,368 | 81,938,839 | -145,983,475 | 81,648,250 | 71,376,678 | 68,924,180 | -137,197,139 | 68,736,125 | |
| Shares (Diluted) | 119,294,615 | 97,879,343 | -168,811,755 | 90,090,397 | 84,412,200 | 83,055,066 | -164,396,186 | 82,485,199 | 82,310,368 | 81,938,839 | -145,983,475 | 81,648,250 | 71,376,678 | 68,924,180 | -137,197,139 | 68,736,125 | |
| EBITDA | $-19M | $-25M | · | $-25M | $-52M | $-76M | · | $-66M | $-72M | $-67M | · | $-50M | $-44M | $-51M | · | $-58M |
Bilan 24
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $182M | $124M | $147M | $166M | $139M | $139M | $132M | $96M | $64M | $69M | $124M | $83M | $221M | $129M | $142M | $211M | |
| Short-term Investments | $30M | · | $0 | $0 | $40M | $82M | $138M | $169M | $215M | $227M | $199M | $267M | $211M | $189M | · | $209M | |
| Receivables | $3M | $3M | $15M | $8M | $588.0K | $510.0K | $16M | $126.0K | $244.0K | $245.0K | $10M | $2M | $2M | $242.0K | · | $120.0K | |
| Prepaid Expense | $4M | $2M | $2M | $3M | $4M | $3M | $3M | $6M | $7M | $9M | $8M | $7M | $7M | $6M | · | $7M | |
| Current Assets | $218M | $128M | $164M | $177M | $183M | $225M | $289M | $271M | $286M | $306M | $341M | $359M | $441M | $324M | · | $427M | |
| PP&E (Net) | $3M | $3M | $4M | $4M | $5M | $8M | $14M | $15M | $14M | $13M | $12M | $12M | $13M | $13M | · | $15M | |
| PP&E (Gross) | $29M | $29M | $32M | $32M | $31M | $36M | $46M | $46M | $43M | $41M | $38M | $37M | $36M | $35M | · | $36M | |
| Accum. Depreciation | $27M | $26M | $28M | $28M | $27M | $28M | $32M | $31M | $29M | $28M | $26M | $25M | $23M | $22M | · | $20M | |
| Other Non-current Assets | $3M | $3M | $3M | $3M | $4M | $4M | $5M | $5M | $8M | $9M | $9M | $6M | $5M | $7M | · | $8M | |
| Total Assets | $237M | $149M | $187M | $202M | $211M | $264M | $342M | $328M | $385M | $440M | $499M | $505M | $542M | $464M | · | $531M | |
| Accounts Payable | $5M | $4M | $3M | $3M | $7M | $5M | $5M | $12M | $14M | $8M | $8M | $10M | $8M | $9M | · | $7M | |
| Accrued Liabilities | $17M | $21M | $33M | $48M | $48M | $47M | $46M | $29M | $28M | $31M | $35M | $30M | $28M | $32M | · | $19M | |
| Current Liabilities | $68M | $40M | $46M | $62M | $66M | $73M | $77M | $72M | $74M | $66M | $63M | $59M | $55M | $57M | · | $42M | |
| Capital Leases | $9M | $11M | $12M | $14M | $15M | $18M | $20M | $22M | $21M | $22M | $24M | $25M | $27M | $29M | · | $9M | |
| Other Non-current Liabilities | $2M | $3M | $3M | $5M | $5M | $6M | $3M | $3M | $4M | $3M | $2M | · | · | · | · | · | |
| Total Liabilities | $132M | $145M | $159M | $188M | $191M | $201M | $207M | $152M | $153M | $146M | $150M | $144M | $142M | $147M | · | $116M | |
| Long-term Debt | $56M | $55M | $59M | $59M | $57M | $55M | $57M | · | · | · | $0 | · | · | · | · | · | |
| Total Debt | $56M | $55M | · | $59M | $57M | $55M | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $15.0K | $10.0K | $10.0K | $9.0K | $9.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $7.0K | · | $7.0K | |
| Retained Earnings | $-1.67B | $-1.65B | $-1.63B | $-1.62B | $-1.60B | $-1.54B | $-1.47B | $-1.42B | $-1.36B | $-1.29B | $-1.23B | $-1.21B | $-1.17B | $-1.13B | · | $-1.02B | |
| AOCI | $-6.0K | $0 | $0 | $0 | $15.0K | $88.0K | $268.0K | $522.0K | $-442.0K | $-326.0K | $198.0K | $-1M | $-2M | $-2M | · | $-4M | |
| Stockholders' Equity | $105M | $4M | $27M | $13M | $19M | $62M | $134M | $176M | $232M | $294M | $349M | $360M | $400M | $317M | $361M | $415M | |
| Liabilities + Equity | $237M | $149M | $187M | $202M | $211M | $264M | $342M | $328M | $385M | $440M | $499M | $505M | $542M | $464M | · | $531M | |
| Shares Outstanding | 97,866,996 | 97,866,996 | 97,866,996 | 93,264,421 | 87,388,425 | 83,709,536 | 82,734,696 | 82,538,624 | 82,429,514 | 82,234,951 | 81,767,263 | 81,668,796 | 81,616,909 | 68,993,591 | · | 68,761,729 |
Flux de trésorerie 10
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $2M | $2M | $2M | $3M | $3M | $4M | $5M | $5M | $8M | $5M | $5M | $5M | $5M | $5M | $6M | |
| Restructuring | · | · | · | · | · | $53M | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-30M | $-23M | $-36M | $-31M | $-50M | $-48M | $-51M | $-53M | $-57M | $-50M | $-22M | $-35M | $-39M | $-36M | $-42M | $-48M | |
| CapEx | $106.0K | $92.0K | $60.0K | $433.0K | $0 | $114.0K | $540.0K | $3M | $3M | $2M | $1M | $239.0K | $1M | $2M | $624.0K | $614.0K | |
| Investing Cash Flow | $-30M | $64.0K | $58.0K | $40M | $43M | $56M | $31M | $84M | $52M | $-5M | $63M | $-103M | $13M | $23M | $-28M | $89M | |
| Stock Issued | $117M | $0 | $17M | $17M | $7M | $1M | $0 | $0 | $0 | $0 | $0 | $0 | · | · | $0 | · | |
| Net Stock Activity | · | $0 | · | · | · | $1M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $118M | $0 | $17M | $17M | $7M | $-1M | $56M | $0 | $322.0K | $192.0K | $514.0K | $0 | $118M | $0 | $619.0K | $80.0K | |
| Net Change in Cash | $58M | $-23M | $-19M | $26M | $-150.0K | $7M | $36M | $31M | $-5M | $-54M | $41M | $-138M | $92M | $-13M | $-69M | $41M | |
| Free Cash Flow | · | $-23M | · | · | · | $-48M | · | · | · | $-52M | · | · | · | $-38M | · | · |
Rentabilité 5
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -156.1% | -883.2% | · | -325.4% | -1440.6% | -1635.1% | · | -107649.2% | -14016.2% | -5902.3% | · | -940.1% | -1527.3% | -517.3% | · | -136952.4% | |
| Net Margin | -153.3% | -882.4% | · | -333.0% | -1487.8% | -1633.5% | · | -101870.5% | -13178.8% | -5458.1% | · | -843.7% | -1395.6% | -497.8% | · | -132681.0% | |
| EBITDA Margin | -156.1% | -883.2% | · | -325.4% | -1440.6% | -1635.1% | · | -107649.2% | -14016.2% | -5902.3% | · | -940.1% | -1527.3% | -517.3% | · | -136952.4% | |
| ROA | -8.1% | -12.1% | · | -9.5% | -17.9% | -21.6% | · | -14.9% | -14.6% | -13.7% | · | -8.7% | -7.2% | -9.0% | · | -8.9% | |
| ROE | -29.3% | -74.8% | · | -26.6% | -42.4% | -42.6% | · | -23.2% | -21.4% | -20.2% | · | -11.6% | -9.3% | -11.8% | · | -11.1% |
Liquidité et Solvabilité 4
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.2 | 3.2 | · | 2.9 | 2.8 | 3.1 | · | 3.7 | 3.9 | 4.6 | · | 6.1 | 8.1 | 5.7 | · | 10.1 | |
| Quick Ratio | 3.1 | 3.2 | · | 2.8 | 2.7 | 3.0 | · | 3.7 | 3.8 | 4.5 | · | 6.0 | 8.0 | 5.6 | · | 9.9 | |
| Debt / Equity | 0.5 | 12.4 | · | 4.4 | 3.0 | 0.9 | · | · | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.5 | 10.7 | · | 4.0 | 2.7 | 0.8 | · | · | · | · | · | · | · | · | · | · |
Efficacité 2
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 7.2 | 1.8 | · | 1.8 | 8.6 | 12.3 | · | 0.0 | 0.4 | 4.7 | · | 4.2 | 1.9 | 12.2 | · | 0.2 |
Valorisation (TTM) 14
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $26M | $19M | · | $16M | $9M | $6M | · | $7M | $10M | $19M | · | $18M | $19M | $23M | · | $19M | |
| Net Income TTM | $-122M | $-179M | · | $-217M | $-259M | $-268M | · | $-237M | $-215M | $-196M | · | $-190M | $-199M | $-209M | · | $-199M | |
| Market Cap | $317M | $242M | · | $324M | $192M | $97M | · | $281M | $385M | $610M | · | $637M | $672M | $500M | · | $842M | |
| Enterprise Value | $161M | $173M | · | $217M | $70M | $-69M | · | · | · | · | · | · | · | · | · | · | |
| P/E | -2.5 | -1.2 | · | -1.3 | -0.7 | -0.4 | · | -1.2 | -1.7 | -2.9 | · | -3.0 | -2.9 | -2.4 | · | -4.2 | |
| P/S | 12.3 | 13.0 | · | 20.4 | 21.8 | 15.3 | · | 40.0 | 39.0 | 31.8 | · | 35.2 | 35.1 | 21.7 | · | 43.4 | |
| P/B | 3.0 | 54.8 | · | 24.1 | 10.0 | 1.6 | · | 1.6 | 1.7 | 2.1 | · | 1.8 | 1.7 | 1.6 | · | 2.0 | |
| P / Tangible Book | 3.0 | 54.8 | · | 24.1 | 10.0 | 1.6 | · | 1.6 | 1.7 | 2.1 | · | 1.8 | 1.7 | 1.6 | · | 2.0 | |
| P / Cash Flow | · | -10.5 | · | · | · | -2.0 | · | · | · | -12.2 | · | · | · | -14.0 | · | · | |
| P / FCF | · | -10.4 | · | · | · | -2.0 | · | · | · | -11.8 | · | · | · | -13.3 | · | · | |
| EV / EBITDA | -8.7 | -6.9 | · | -8.8 | -1.4 | 0.9 | · | · | · | · | · | · | · | · | · | · | |
| EV / FCF | · | -7.5 | · | · | · | 1.4 | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 6.2 | 9.3 | · | 13.7 | 8.0 | -10.9 | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -40.7% | -84.6% | · | -74.4% | -141.8% | -280.2% | · | -84.5% | -57.6% | -34.8% | · | -33.7% | -34.8% | -41.9% | · | -23.7% |
États financiers Compte de résultat, bilan, flux de trésorerie — annuel, sur les 5 dernières années
Compte de résultat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Revenu | $41M | $32M | $78M | $20M | $26M |
| Marge d'exploitation % | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% |
| Résultat net | $-160M | $-237M | $-153M | $-220M | $-193M |
| BPA dilué | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 |
Bilan
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Dette / Capitaux propres | 2.1 | 0.4 | — | — | — |
| Ratio de liquidité | 3.5 | 3.7 | 5.4 | 5.9 | 10.8 |
| Ratio de liquidité réduite | 3.5 | 3.7 | 5.3 | 5.8 | 10.7 |
Flux de trésorerie
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flux de trésorerie libre | $-166M | $-219M | $-137M | $-181M | $-172M |
Mes métriques Votre watchlist personnelle — lignes sélectionnées de Fondamentaux Complets
📊
Choisissez les indicateurs qui vous importent — cliquez sur le ➕ à côté de n'importe quelle ligne dans Fondamentaux Complets ci-dessus.
Votre sélection est enregistrée et vous suit sur tous les tickers.
Détenteurs institutionnels (13F) 239 déclarants · $327.2M total · Au 30 juin 2026
Institutions qui déclarent détenir cette action dans leur Formulaire SEC 13F trimestriel. Uniquement les positions longues ; un même déclarant peut apparaître deux fois pour des jambes d'options distinctes. Les jambes put/call compensatoires importantes reflètent généralement la tenue de marché ou un inventaire couvert, pas une conviction directionnelle.
Activité institutionnelle — Q2 2026 vs trimestre précédent
| Nouvelles positions | Positions clôturées | Augmenté | Diminué | Variation nette des actions |
|---|---|---|---|---|
| 41 (-2 vs T. préc.) | 22 (-4 vs T. préc.) | 76 (+20 vs T. préc.) | 42 (-9 vs T. préc.) | +67.4M |
Comparé à Q1 2026. Les dépôts de formulaire 13F de la SEC sont dus dans les 45 jours suivant la fin du trimestre, plus une courte période tampon pour les déposants tardifs — les trimestres encore dans cette fenêtre sont ignorés au profit de la paire la plus récente entièrement déclarée.
| Institution | Valeur | Actions | % de 13F suivies | Type |
|---|---|---|---|---|
| TCG Crossover Management, LLC | $36 000 000 | 11 111 111 | 11,00% | Actions |
| RA CAPITAL MANAGEMENT, L.P. | $28 800 360 | 8 889 000 | 8,80% | Actions |
| Commodore Capital LP | $28 800 360 | 8 889 000 | 8,80% | Actions |
| ADAR1 Capital Management, LLC | $28 800 360 | 8 889 000 | 8,80% | Actions |
| VANGUARD CAPITAL MANAGEMENT LLC | $19 897 929 | 6 141 336 | 6,08% | Actions |
| Paradigm Biocapital Advisors LP | $18 100 665 | 5 586 625 | 5,53% | Actions |
| Opaleye Management Inc. | $12 512 653 | 3 861 930 | 3,82% | Actions |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $11 658 618 | 3 598 339 | 3,56% | Actions |
| Woodline Partners LP | $11 519 810 | 3 555 497 | 3,52% | Actions |
| Vivo Capital, LLC | $11 519 010 | 3 555 250 | 3,52% | Actions |
| GordonMD Global Investments LP | $10 131 480 | 3 127 000 | 3,10% | Actions |
| RENAISSANCE TECHNOLOGIES LLC | $7 999 298 | 2 468 919 | 2,45% | Actions |
| Logos Global Management LP | $7 199 280 | 2 222 000 | 2,20% | Actions |
| GEODE CAPITAL MANAGEMENT, LLC | $7 134 030 | 2 201 290 | 2,18% | Actions |
| STATE STREET CORP | $7 101 442 | 2 191 803 | 2,17% | Actions |
| GOLDMAN SACHS GROUP INC | $6 763 843 | 2 087 606 | 2,07% | Actions |
| TWO SIGMA INVESTMENTS, LP | $4 318 842 | 1 332 976 | 1,32% | Actions |
| Seven Fleet Capital Management LP | $4 310 820 | 1 330 500 | 1,32% | Actions |
| RAYMOND JAMES FINANCIAL INC | $4 201 156 | 1 296 653 | 1,28% | Actions |
| MARSHALL WACE, LLP | $4 044 048 | 1 248 163 | 1,24% | Actions |
| D. E. Shaw & Co., Inc. | $3 715 178 | 1 146 660 | 1,14% | Actions |
| KENNEDY CAPITAL MANAGEMENT LLC | $3 344 111 | 1 032 133 | 1,02% | Actions |
| MACKENZIE FINANCIAL CORP | $2 844 856 | 878 042 | 0,87% | Actions |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $2 812 424 | 868 032 | 0,86% | Actions |
| Nantahala Capital Management, LLC | $2 762 748 | 852 700 | 0,84% | Actions |
| TWO SIGMA ADVISERS, LP | $2 509 405 | 1 224 100 | 0,77% | Actions |
| VANGUARD FIDUCIARY TRUST CO | $2 407 158 | 742 950 | 0,74% | Actions |
| BlackRock, Inc. | $1 813 920 | 559 852 | 0,55% | Actions |
| MILLENNIUM MANAGEMENT LLC | $1 616 750 | 498 997 | 0,49% | Actions |
| Susquehanna Portfolio Strategies, LLC | $1 545 801 | 477 099 | 0,47% | Actions |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1 521 180 | 469 500 | 0,46% | Option d'achat |
| Eversept Partners, LP | $1 486 541 | 458 809 | 0,45% | Actions |
| Casdin Capital, LLC | $1 441 800 | 445 000 | 0,44% | Actions |
| PEAK6 LLC | $1 346 029 | 415 441 | 0,41% | Actions |
| DIADEMA PARTNERS LP | $1 296 000 | 400 000 | 0,40% | Option d'achat |
| BIT Capital GmbH | $1 056 240 | 326 000 | 0,32% | Actions |
| Cubist Systematic Strategies, LLC | $994 094 | 286 482 | 0,30% | Actions |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $878 642 | 271 186 | 0,27% | Actions |
| BANK OF AMERICA CORP /DE/ | $751 119 | 231 827 | 0,23% | Actions |
| LPL Financial LLC | $748 813 | 231 115 | 0,23% | Actions |
| Erste Asset Management GmbH | $736 000 | 230 000 | 0,22% | Actions |
| IEQ CAPITAL, LLC | $705 623 | 217 785 | 0,22% | Actions |
| Walleye Capital LLC | $595 703 | 183 859 | 0,18% | Actions |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $558 900 | 172 500 | 0,17% | Option de vente |
| CITADEL ADVISORS LLC | $557 604 | 172 100 | 0,17% | Option de vente |
| DAFNA Capital Management LLC | $552 323 | 170 470 | 0,17% | Actions |
| Mariner, LLC | $548 500 | 169 291 | 0,17% | Actions |
| Green Alpha Advisors, LLC | $505 589 | 156 046 | 0,15% | Actions |
| PEAK6 LLC | $497 340 | 153 500 | 0,15% | Option d'achat |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $490 555 | 151 406 | 0,15% | Actions |
| BARCLAYS PLC | $476 030 | 146 923 | 0,15% | Actions |
| ALLIANCEBERNSTEIN L.P. | $464 187 | 187 930 | 0,14% | Actions |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $445 030 | 137 355 | 0,14% | Actions |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $408 240 | 126 000 | 0,12% | Actions |
| Point72 Asset Management, L.P. | $405 758 | 125 234 | 0,12% | Actions |
| RHUMBLINE ADVISERS | $380 421 | 117 417 | 0,12% | Actions |
| JPMORGAN CHASE & CO | $376 528 | 117 665 | 0,12% | Actions |
| JANE STREET GROUP, LLC | $374 473 | 115 578 | 0,11% | Actions |
| FMR LLC | $348 384 | 107 526 | 0,11% | Actions |
| HSBC HOLDINGS PLC | $314 481 | 97 062 | 0,10% | Actions |
| Bank of New York Mellon Corp | $309 378 | 95 487 | 0,09% | Actions |
| WELLINGTON MANAGEMENT GROUP LLP | $303 462 | 93 661 | 0,09% | Actions |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $300 818 | 92 845 | 0,09% | Actions |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | $300 226 | 92 094 | 0,09% | Actions |
| AMERICAN CENTURY COMPANIES INC | $300 011 | 92 596 | 0,09% | Actions |
| CWM, LLC | $259 352 | 105 001 | 0,08% | Actions |
| MORGAN STANLEY | $237 324 | 73 248 | 0,07% | Actions |
| CITADEL ADVISORS LLC | $229 392 | 70 800 | 0,07% | Option d'achat |
| OSAIC HOLDINGS, INC. | $222 928 | 68 806 | 0,07% | Actions |
| SEI INVESTMENTS CO | $221 188 | 68 268 | 0,07% | Actions |
| Nuveen, LLC | $221 188 | 68 268 | 0,07% | Actions |
| Joel Isaacson & Co., LLC | $220 787 | 68 144 | 0,07% | Actions |
| JANE STREET GROUP, LLC | $218 376 | 67 400 | 0,07% | Option de vente |
| SIMPLEX TRADING, LLC | $207 275 | 63 974 | 0,06% | Actions |
| MetLife Investment Management, LLC | $182 140 | 56 216 | 0,06% | Actions |
| CITIGROUP INC | $182 052 | 56 189 | 0,06% | Actions |
| CITADEL ADVISORS LLC | $173 923 | 53 680 | 0,05% | Actions |
| MML INVESTORS SERVICES, LLC | $168 765 | 52 088 | 0,05% | Actions |
| GROUP ONE TRADING LLC | $163 131 | 50 349 | 0,05% | Actions |
| Creative Planning | $147 653 | 45 572 | 0,05% | Actions |
| China Universal Asset Management Co., Ltd. | $143 934 | 44 424 | 0,04% | Actions |
| WINTON GROUP Ltd | $141 588 | 43 700 | 0,04% | Actions |
| Vanguard Global Advisers, LLC | $138 876 | 42 863 | 0,04% | Actions |
| CANADA PENSION PLAN INVESTMENT BOARD | $137 376 | 42 400 | 0,04% | Actions |
| Graham Capital Management, L.P. | $134 369 | 41 472 | 0,04% | Actions |
| Quinn Opportunity Partners LLC | $129 600 | 40 000 | 0,04% | Actions |
| Invesco Ltd. | $128 178 | 39 561 | 0,04% | Actions |
| Vanguard Personalized Indexing Management, LLC | $124 108 | 38 305 | 0,04% | Actions |
| MERCER GLOBAL ADVISORS INC /ADV | $121 967 | 37 644 | 0,04% | Actions |
| Balyasny Asset Management L.P. | $121 947 | 37 638 | 0,04% | Actions |
| AXQ CAPITAL, LP | $118 104 | 36 452 | 0,04% | Actions |
| Nuveen Asset Management, LLC | $113 934 | 89 712 | 0,03% | Actions |
| SCS Capital Management LLC | $113 400 | 35 000 | 0,03% | Actions |
| Police & Firemen's Retirement System of New Jersey | $109 749 | 33 873 | 0,03% | Actions |
| Thrive Wealth Management, LLC | $108 540 | 33 500 | 0,03% | Actions |
| TWO SIGMA SECURITIES, LLC | $107 367 | 33 138 | 0,03% | Actions |
| INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC | $102 359 | 31 207 | 0,03% | Actions |
| CAPTRUST FINANCIAL ADVISORS | $98 159 | 30 296 | 0,03% | Actions |
| HORIZON KINETICS ASSET MANAGEMENT LLC | $89 683 | 27 680 | 0,03% | Actions |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $88 339 | 27 265 | 0,03% | Actions |
Initiés de la société 32 initiés · 13 dirigeants · 15 administrateurs
| Dirigeant | Rôle | Dernière activité | Actions détenues | Achats 12m | Ventes 12m | Net 12m |
|---|---|---|---|---|---|---|
| Gilmore Neil O'Neill | CEO | 3 juin 2026 S | 248 313 | 0 | 1 | $-41 543 |
| MULLEN JAMES C | CEO | 3 janvier 2022 S | 75 898 | 0 | 0 | $0 |
| Cynthia Collins | CEO | 9 février 2021 S | 43 760 | 0 | 0 | $0 |
| Katrine Bosley | President and CEO | 8 janvier 2019 S | 1 204 966 | 0 | 0 | $0 |
| Michelle Robertson | Chief Financial Officer | 11 janvier 2022 S | 31 462 | 0 | 0 | $0 |
| Andrew A. F. Hack | Chief Financial Officer | 4 février 2019 M | 0 | 0 | 0 | $0 |
| Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | 28 juillet 2026 S | 62 369 | 0 | 2 | $-15 133 |
| Bruce Eaton | EVP, Chief Business Officer | 22 décembre 2021 A | 31 498 | 0 | 0 | $0 |
| Lisa Anne Michaels | EVP/Chief Medical Officer | 22 décembre 2021 A | 22 675 | 0 | 0 | $0 |
| Mark S Shearman | EVP, Chief Scientific Officer | 22 décembre 2021 A | 41 785 | 0 | 0 | $0 |
| Judith R Abrams | Chief Medical Officer | 28 octobre 2019 A | 25 000 | 0 | 0 | $0 |
| Vickesh Myer | Chief Technology Officer | 18 mars 2019 M | 0 | 0 | 0 | $0 |
| Gerald Frank Cox | Chief Medical Officer | 7 février 2018 A | 4 000 | 0 | 0 | $0 |
| Elliott M. Levy | Administrateur | 17 juin 2026 A | — | 0 | 0 | $0 |
| David Scadden | Administrateur | 17 juin 2026 A | — | 0 | 0 | $0 |
| Bernadette Connaughton | Administrateur | 17 juin 2026 A | — | 0 | 0 | $0 |
| Jessica Hopfield | Administrateur | 17 juin 2026 A | 22 700 | 0 | 0 | $0 |
| Andrew Hirsch | Administrateur | 17 juin 2026 A | — | 0 | 0 | $0 |
| Emma Reeve | Administrateur | 3 septembre 2021 A | — | 0 | 0 | $0 |
| Meeta Chatterjee | Administrateur | 3 juin 2021 A | — | 0 | 0 | $0 |
| Boris Nikolic | Administrateur | 15 juin 2018 A | 35 000 | 0 | 0 | $0 |
| Douglas G. Cole | Administrateur | 17 août 2017 J | 3 171 | 0 | 0 | $0 |
| Kevin Bitterman | Administrateur | 15 juin 2017 A | 2 797 144 | 0 | 0 | $0 |
| Alexis Borisy | Administrateur | 15 juin 2017 A | 0 | 0 | 0 | $0 |
| John Mendlein | Administrateur | 15 juin 2017 A | — | 0 | 0 | $0 |
| Kevin P Starr | Détenteur de 10% | 6 septembre 2016 S | 0 | 0 | 0 | $0 |
| bng0, LLC | Détenteur de 10% | 8 février 2016 C | 2 649 572 | 0 | 0 | $0 |
| Patrick Thomas Ellinor II | — | 6 août 2026 A | — | 0 | 0 | $0 |
| Amy Parison | — | 3 août 2026 S | 14 292 | 0 | 2 | $-3 002 |
| Akshay Vaishnaw | — | 3 juin 2021 A | — | 0 | 0 | $0 |
| Charles Albright | — | 15 décembre 2020 M | 24 907 | 0 | 0 | $0 |
| Alexandra Glucksmann | — | 15 mars 2017 M | 117 788 | 0 | 0 | $0 |
Initiés issus des déclarations SEC Form 3/4/5 ; net = uniquement P/S de marché
Activistes et détenteurs de 5%+ 1 participation
Investisseurs ayant déposé un Schedule 13D auprès de la SEC — détention effective supérieure à 5% avec l'intention d'influencer l'émetteur (participations activistes, campagnes pour le conseil d'administration, fusions-acquisitions). Chaque ligne montre le dernier état connu de la position du déposant.
| Déclarant | Déposé | Participation | Statut | Objectif | Dépôt |
|---|---|---|---|---|---|
| Polaris Venture Partners VI, L.P. (“PVP VI”), Polaris Venture Founders’ Fund VI, L.P. (“PVPFF VI”), Polaris Venture Management Co. VI, L.L.C. (“PVM VI”), Jonathan A. Flint (“Flint”), Terrance G. McGuire (“McGuire”), Brian Chee (“Chee”), David Barrett (“Barrett”), Amir Nashat (“Nashat”), Bryce Youngren (“Youngren”) ×4 dépôts | 18 septembre 2017 | — | Dépôt initial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Détention d'ETF Détenu par 28 ETFs
Le poids reflète uniquement les participations directes en actions (N-PORT) ; les fonds à effet de levier ou basés sur des dérivés peuvent détenir une exposition supplémentaire aux swaps non indiquée.
| Fonds | Poids | Unités | Au | Source |
|---|---|---|---|---|
| GNOM · Global X Funds | 0,34% | 54 725 NS | 31 mai 2026 | N-PORT |
| BIB · ProShares Trust | 0,02% | 3 611 NS | 31 mai 2026 | N-PORT |
| TMFX · RBB Fund, Inc. | 0,02% | 1 527 NS | 31 mai 2026 | N-PORT |
| RSSL · Global X Funds | 0,01% | 42 610 NS | 30 avril 2026 | N-PORT |
| ITWO · ProShares Trust | 0,01% | 4 633 NS | 31 mai 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,01% | 476 309 NS | 31 mai 2026 | N-PORT |
| UWM · ProShares Trust | 0,01% | 3 622 NS | 31 mai 2026 | N-PORT |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,00% | 32 379 NS | 31 mai 2026 | N-PORT |
| URTY · ProShares Trust | 0,00% | 3 660 NS | 31 mai 2026 | N-PORT |
| HDG · ProShares Trust | 0,00% | 92 NS | 31 mai 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,00% | 2 922 NS | 31 mai 2026 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 96 350 NS | 31 mai 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | — | — | 15 juillet 2026 | Quotidien |
| VTI · VANGUARD INDEX FUNDS | — | — | 15 juillet 2026 | Quotidien |
| VTWO · VANGUARD SCOTTSDALE FUNDS | — | — | 15 juillet 2026 | Quotidien |
| VTWV · VANGUARD SCOTTSDALE FUNDS | — | — | 15 juillet 2026 | Quotidien |
| VTWG · VANGUARD SCOTTSDALE FUNDS | — | — | 15 juillet 2026 | Quotidien |
| VTHR · VANGUARD SCOTTSDALE FUNDS | — | — | 15 juillet 2026 | Quotidien |
| IWV · iShares Trust | — | — | 18 août 2026 | Quotidien |
| IWN · iShares Trust | — | — | 17 août 2026 | Quotidien |
| IWO · iShares Trust | — | — | 18 août 2026 | Quotidien |
| IWM · iShares Trust | — | — | 18 août 2026 | Quotidien |
| IBB · iShares Trust | — | — | 18 août 2026 | Quotidien |
| IWC · iShares Trust | — | — | 18 août 2026 | Quotidien |
| PRFZ · Invesco Exchange-Traded Fund Trust | — | — | 13 juillet 2026 | Quotidien |
| VHT · VANGUARD WORLD FUND | — | — | 20 juillet 2026 | Quotidien |
| IBBQ · Invesco Exchange-Traded Fund Trust … | — | — | 20 juillet 2026 | Quotidien |
| QQQS · Invesco Exchange-Traded Fund Trust … | — | — | 20 juillet 2026 | Quotidien |